Electromed Inc (ELMD) 2.35 $ELMD
Electromed ups revenues 40% in FQ2
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:50AM CST
ELMD: 2.35 (-0.15)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 4:39PM CST
BXE: 2.79 (+0.05), NOG: 8.76 (+0.38), IPHI: 19.17 (-1.48), PIR: 12.52 (+0.17), KEG: 2.14 (+0.08), CNQ: 31.63 (+0.45), SSNI: 9.15 (+0.36), GNW: 8.67 (+0.17), CHS: 18.38 (+0.10), ELMD: 2.35 (-0.15)
Electromed beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:56PM CST
ELMD: 2.35 (-0.15)
Electromed, Inc. Reports Higher Second Quarter Revenues and Profits
Business Wire - Tue Feb 10, 3:30PM CST
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three-and six-month periods ended December 31, 2014. Net revenues for the second quarter of fiscal 2015 rose approximately 40% to $4.9 million, compared to $3.5 million in the same quarter of fiscal 2014. The Company reported net income of $423,000, or $0.05 cents per basic and diluted share, for the second quarter of fiscal 2015, compared to a net loss of $239,000, or ($0.03) per basic and diluted share, for the same period of fiscal 2014.
ELMD: 2.35 (-0.15)
Volcano's Prospects Bright in Image-Guided Therapy Market - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 5:00PM CST
Volcano (VOLC) reported adjusted loss per share of 4 cents in the quarter, narrower than the Zacks Consensus Estimate by 20%.
ABMD: 60.39 (+0.46), PHG: 28.93 (-0.07), VOLC: 17.98 (+0.03), ELMD: 2.35 (-0.15)
Thoratec (THOR) Downgraded to Strong Sell after Dismal Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 1:40PM CST
Thoratec Corp.'s (THOR) lackluster third-quarter 2014 results, with both earnings and revenues missing expectations, have set a negative earnings estimate revision trend for the company.
ABMD: 60.39 (+0.46), EW: 134.23 (+1.89), THOR: 40.01 (+0.54), ELMD: 2.35 (-0.15)
Bioanalytical Systems Q4 Loss Widens, Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:00AM CST
Bioanalytical Systems, Inc. (BASI) reported fourth quarter fiscal 2014 loss of 2 cents per share, which doubled from the year-ago loss of a penny
FLDM: 37.93 (-0.47), BASI: 2.06 (+0.18), INGN: 33.53 (+2.32), ELMD: 2.35 (-0.15)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:45AM CST
LTBR: 1.40 (+0.18), ASPS: 22.32 (+0.09), AETI: 5.00 (+0.26), PLUG: 3.15 (unch), MOC: 2.24 (+0.02), CRDS: 2.32 (+0.05), STKL: 11.59 (-0.07), BIOC: 1.41 (+0.22), CZR: 10.78 (+0.18), MATX: 38.15 (+0.54), NTIC: 21.00 (-0.90), SDPI: 3.25 (-0.08), RESN: 16.62 (-1.38), OREX: 5.55 (+0.10), FLL: 1.47 (-0.03), VGGL: 1.77 (-0.08), CGG: 6.86 (+0.06), SUSQ: 13.48 (+0.01), SINO: 1.50 (unch), ELMD: 2.35 (-0.15)
Electromed, Inc. Reports Higher First Quarter Revenues and Profits
Business Wire - Wed Nov 12, 8:01AM CST
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three-month period ended September 30, 2014. Net revenues for the first quarter of fiscal 2015 rose approximately 40% to $4.8 million, compared to $3.4 million in the first quarter of fiscal 2014. The Company reported net income of $378,000, or $0.05 cents per basic and diluted share, for the first quarter of fiscal 2015, compared to a net loss of $335,000, or ($0.04) cents per basic and diluted share, for the same period of fiscal 2014.
ELMD: 2.35 (-0.15)
Masimo Beats Q3 Earnings Estimates, Cuts Revenue Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 12:49PM CDT
Masimo Corp (MASI) reported earnings of 27 cents per share in the third quarter of 2014, which beat the Zacks Consensus Estimate by a couple of cents
ATEC: 1.34 (unch), MASI: 27.38 (-0.21), CYNO: 31.37 (+0.80), ELMD: 2.35 (-0.15)
Electromed (ELMD) Upgraded From Sell to Hold
at The Street - Fri Sep 26, 8:05AM CDT
Electromed (ELMD) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
ELMD: 2.35 (-0.15)
Electromed jumps to net income of USD290,000 and revenues up 14.8% for Q4 fiscal 2014
M2 - Wed Sep 24, 7:39AM CDT
Airway clearance therapy company Electromed (NYSE MKT:ELMD) disclosed on Tuesday its net income of USD290,000 (USD0.04 per basic and diluted share) for its fourth quarter ended 30 June 2014.
ELMD: 2.35 (-0.15)
Electromed, Inc. Reports a Profit on Higher Fiscal 2014 Fourth Quarter Revenues
Business Wire - Tue Sep 23, 3:30PM CDT
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for its fourth quarter and fiscal year ended June 30, 2014.
ELMD: 2.35 (-0.15)
Electromed, Inc. Names Lee Jones to its Board of Directors
Business Wire - Tue Sep 02, 3:30PM CDT
Electromed, Inc. (NASDAQ: ELMD), announced today that its Board of Directors has elected Lee Jones to the Board. Ms. Jones has served as the President and Chief Executive Officer of Rebiotix Inc. since 2011 and as a director of Uroplasty, Inc. since 2006.
UPI: 1.27 (unch), ELMD: 2.35 (-0.15)
Electromed ups revenues 40% in FQ2
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:50AM CST
ELMD: 2.35 (-0.15)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 4:39PM CST
BXE: 2.79 (+0.05), NOG: 8.76 (+0.38), IPHI: 19.17 (-1.48), PIR: 12.52 (+0.17), KEG: 2.14 (+0.08), CNQ: 31.63 (+0.45), SSNI: 9.15 (+0.36), GNW: 8.67 (+0.17), CHS: 18.38 (+0.10), ELMD: 2.35 (-0.15)
Electromed beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 3:56PM CST
ELMD: 2.35 (-0.15)
Electromed, Inc. Reports Higher Second Quarter Revenues and Profits
Business Wire - Tue Feb 10, 3:30PM CST
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three-and six-month periods ended December 31, 2014. Net revenues for the second quarter of fiscal 2015 rose approximately 40% to $4.9 million, compared to $3.5 million in the same quarter of fiscal 2014. The Company reported net income of $423,000, or $0.05 cents per basic and diluted share, for the second quarter of fiscal 2015, compared to a net loss of $239,000, or ($0.03) per basic and diluted share, for the same period of fiscal 2014.
ELMD: 2.35 (-0.15)
Volcano's Prospects Bright in Image-Guided Therapy Market - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 5:00PM CST
Volcano (VOLC) reported adjusted loss per share of 4 cents in the quarter, narrower than the Zacks Consensus Estimate by 20%.
ABMD: 60.39 (+0.46), PHG: 28.93 (-0.07), VOLC: 17.98 (+0.03), ELMD: 2.35 (-0.15)
Thoratec (THOR) Downgraded to Strong Sell after Dismal Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 1:40PM CST
Thoratec Corp.'s (THOR) lackluster third-quarter 2014 results, with both earnings and revenues missing expectations, have set a negative earnings estimate revision trend for the company.
ABMD: 60.39 (+0.46), EW: 134.23 (+1.89), THOR: 40.01 (+0.54), ELMD: 2.35 (-0.15)
Bioanalytical Systems Q4 Loss Widens, Revenues Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:00AM CST
Bioanalytical Systems, Inc. (BASI) reported fourth quarter fiscal 2014 loss of 2 cents per share, which doubled from the year-ago loss of a penny
FLDM: 37.93 (-0.47), BASI: 2.06 (+0.18), INGN: 33.53 (+2.32), ELMD: 2.35 (-0.15)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:45AM CST
LTBR: 1.40 (+0.18), ASPS: 22.32 (+0.09), AETI: 5.00 (+0.26), PLUG: 3.15 (unch), MOC: 2.24 (+0.02), CRDS: 2.32 (+0.05), STKL: 11.59 (-0.07), BIOC: 1.41 (+0.22), CZR: 10.78 (+0.18), MATX: 38.15 (+0.54), NTIC: 21.00 (-0.90), SDPI: 3.25 (-0.08), RESN: 16.62 (-1.38), OREX: 5.55 (+0.10), FLL: 1.47 (-0.03), VGGL: 1.77 (-0.08), CGG: 6.86 (+0.06), SUSQ: 13.48 (+0.01), SINO: 1.50 (unch), ELMD: 2.35 (-0.15)
Electromed, Inc. Reports Higher First Quarter Revenues and Profits
Business Wire - Wed Nov 12, 8:01AM CST
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for the three-month period ended September 30, 2014. Net revenues for the first quarter of fiscal 2015 rose approximately 40% to $4.8 million, compared to $3.4 million in the first quarter of fiscal 2014. The Company reported net income of $378,000, or $0.05 cents per basic and diluted share, for the first quarter of fiscal 2015, compared to a net loss of $335,000, or ($0.04) cents per basic and diluted share, for the same period of fiscal 2014.
ELMD: 2.35 (-0.15)
Masimo Beats Q3 Earnings Estimates, Cuts Revenue Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 12:49PM CDT
Masimo Corp (MASI) reported earnings of 27 cents per share in the third quarter of 2014, which beat the Zacks Consensus Estimate by a couple of cents
ATEC: 1.34 (unch), MASI: 27.38 (-0.21), CYNO: 31.37 (+0.80), ELMD: 2.35 (-0.15)
Electromed (ELMD) Upgraded From Sell to Hold
at The Street - Fri Sep 26, 8:05AM CDT
Electromed (ELMD) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
ELMD: 2.35 (-0.15)
Electromed jumps to net income of USD290,000 and revenues up 14.8% for Q4 fiscal 2014
M2 - Wed Sep 24, 7:39AM CDT
Airway clearance therapy company Electromed (NYSE MKT:ELMD) disclosed on Tuesday its net income of USD290,000 (USD0.04 per basic and diluted share) for its fourth quarter ended 30 June 2014.
ELMD: 2.35 (-0.15)
Electromed, Inc. Reports a Profit on Higher Fiscal 2014 Fourth Quarter Revenues
Business Wire - Tue Sep 23, 3:30PM CDT
Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for its fourth quarter and fiscal year ended June 30, 2014.
ELMD: 2.35 (-0.15)
Electromed, Inc. Names Lee Jones to its Board of Directors
Business Wire - Tue Sep 02, 3:30PM CDT
Electromed, Inc. (NASDAQ: ELMD), announced today that its Board of Directors has elected Lee Jones to the Board. Ms. Jones has served as the President and Chief Executive Officer of Rebiotix Inc. since 2011 and as a director of Uroplasty, Inc. since 2006.
UPI: 1.27 (unch), ELMD: 2.35 (-0.15)
